Watson Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for WATSON LABS, and what generic and branded alternatives to WATSON LABS drugs are available?
WATSON LABS has one thousand and thirty-two approved drugs.
There are eighteen tentative approvals on WATSON LABS drugs.
Drugs and US Patents for Watson Labs
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs | SULFASALAZINE | sulfasalazine | TABLET;ORAL | 084964-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Watson Labs | ORPHENADRINE CITRATE | orphenadrine citrate | TABLET, EXTENDED RELEASE;ORAL | 084303-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Watson Labs | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | acetaminophen; hydrocodone bitartrate | TABLET;ORAL | 040122-002 | Mar 4, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Watson Labs Inc | SILDENAFIL CITRATE | sildenafil citrate | TABLET;ORAL | 202503-001 | Nov 6, 2012 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Watson Labs | METOCLOPRAMIDE HYDROCHLORIDE | metoclopramide hydrochloride | TABLET;ORAL | 070363-001 | Mar 2, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for WATSON LABS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
Similar Applicant Names
Here is a list of applicants with similar names.